Focus Partners Wealth Purchases 44,260 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Focus Partners Wealth increased its holdings in Halozyme Therapeutics by 57.8%, purchasing 44,260 additional shares, and now owns a total of 120,815 shares valued at approximately $7.7 million.
• Insider selling has been reported, with CFO Nicole Labrosse and CEO Helen Torley selling 20,000 shares each, resulting in respective decreases of 45.14% and 2.65% in their positions.
• Halozyme Therapeutics' stock has experienced a slight decline of 0.8%; however, it has shown robust financial performance with a reported EPS of $1.54 for the recent quarter, exceeding expectations.

Focus Partners Wealth grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 57.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,815 shares of the biopharmaceutical company's stock after buying an additional 44,260 shares during the period. Focus Partners Wealth owned 0.10% of Halozyme Therapeutics worth $7,709,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of HALO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Halozyme Therapeutics by 4.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,087 shares of the biopharmaceutical company's stock worth $4,117,000 after acquiring an additional 3,874 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 28.8% during the fourth quarter. ProShare Advisors LLC now owns 47,114 shares of the biopharmaceutical company's stock valued at $2,253,000 after purchasing an additional 10,531 shares during the last quarter. Rafferty Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 16.4% in the 4th quarter. Rafferty Asset Management LLC now owns 219,392 shares of the biopharmaceutical company's stock worth $10,489,000 after buying an additional 30,852 shares during the last quarter. Shay Capital LLC bought a new position in Halozyme Therapeutics during the 4th quarter valued at approximately $215,000. Finally, Steamboat Capital Partners LLC increased its position in Halozyme Therapeutics by 43.6% during the 4th quarter. Steamboat Capital Partners LLC now owns 249,751 shares of the biopharmaceutical company's stock valued at $11,941,000 after buying an additional 75,890 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Nicole Labrosse sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares in the company, valued at $1,840,207.26. This represents a 45.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $54,618,042.36. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 124,000 shares of company stock valued at $7,830,320 in the last quarter. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Down 0.8%

Shares of Halozyme Therapeutics stock opened at $76.90 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $77.60. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The company's 50 day moving average is $65.11 and its 200 day moving average is $60.47. The company has a market cap of $8.99 billion, a price-to-earnings ratio of 17.60, a price-to-earnings-growth ratio of 0.43 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. During the same quarter in the previous year, the company posted $0.91 earnings per share. Halozyme Therapeutics's revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

HALO has been the topic of a number of recent research reports. HC Wainwright increased their target price on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Zacks Research raised shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 2nd. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Finally, Morgan Stanley raised their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research report on Monday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $67.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.